Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Chi Soo Kang"'
Autor:
Xiang Sun, Chi Soo Kang, Inseok Sin, Shuyuan Zhang, Siyuan Ren, Haixing Wang, Dijie Liu, Michael R. Lewis, Hyun-Soon Chong
Publikováno v:
ACS Omega, Vol 5, Iss 44, Pp 28615-28620 (2020)
Externí odkaz:
https://doaj.org/article/5bfc85b08afd4e02bbd892d624b2b142
Autor:
Inki Lee, Byung Hyun Byun, Byung Il Kim, Chang Woon Choi, Hye Jin Kang, Chi Soo Kang, Sang-Keun Woo, Kyo Chul Lee, Joo Hyun Kang, Ilhan Lim
Publikováno v:
Nuclear Medicine Communications; Oct2024, Vol. 45 Issue 10, p865-873, 9p
Autor:
Dr. Joo Hee Jang, Sang Jin Han, Dr. Jung Young Kim, Dr. Kwang Il Kim, Dr. Kyo Chul Lee, Dr. Chi Soo Kang
Publikováno v:
ChemistryOpen, Vol 8, Iss 4, Pp 451-456 (2019)
Abstract The preparation and in vitro evaluation of a theranostic conjugate composed of trastuzumab, paclitaxel (PTX), and deferoxamine (DFO)‐chelated 89Zr have been reported. These comounds have potential applications against HER2 receptor positiv
Externí odkaz:
https://doaj.org/article/7528fd4459db405592ddcabbdfe9459c
Autor:
Chi Soo Kang, Shuyuan Zhang, Haixing Wang, Yujie Liu, Siyuan Ren, Yanda Chen, Jingbai Li, Nilantha Bandara, Andrey Yu Rogachev, Buck E. Rogers, Hyun-Soon Chong
Publikováno v:
ACS Omega. 7:37229-37236
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17f6ce55f49a1b47186330bdc96ba5aa
https://doi.org/10.1021/acsomega.2c03478
https://doi.org/10.1021/acsomega.2c03478
Publikováno v:
Nuclear Medicine and Biology. :S125-S126
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b1327c97a306fdc4b16447531fdd760
https://doi.org/10.1016/s0969-8051(22)00276-1
https://doi.org/10.1016/s0969-8051(22)00276-1
Autor:
Joo Hee Jang, M. T. Jeena, Suk Won Hwang, Yuri Cho, Eun Min Go, Chi Soo Kang, Sehoon Kim, Ja-Hyoung Ryu, Eunji Lee, Seokyung Lee, Seongeon Jin, Sang Kyu Kwak, Keunsoo Jeong, Woo Young Bang
Publikováno v:
ACS Nano. 13:11022-11033
Self-assembly of peptides containing both l- and d-isomers often results in nanostructures with enhanced properties compared to their enantiomeric analogues, such as faster kinetics of formation, higher mechanical strength, and enzymatic stability. H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54bd5f35ab6e8a0e5ef35279798ea34d
https://doi.org/10.1021/acsnano.9b02522
https://doi.org/10.1021/acsnano.9b02522
Publikováno v:
ChemistryOpen
The preparation and in vitro evaluation of a theranostic conjugate composed of trastuzumab, paclitaxel (PTX), and deferoxamine (DFO)‐chelated 89Zr have been reported. These comounds have potential applications against HER2 receptor positive breast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eed70b4b3cc8ec7b02bdd0ebd4f93f9f
https://doi.org/10.1002/open.201900037
https://doi.org/10.1002/open.201900037
Publikováno v:
Journal of Inorganic Biochemistry. 221:111436
Targeted radionuclide therapy is a developing therapeutic modality for cancer and employs a cytotoxic radionuclide bound to a chelating agent and a bioactive molecule with high binding affinity for a specific biomarker in tumors. An optimal chelator
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::411b78a8ff6a6da5ee9c4cf46e80c6f6
https://doi.org/10.1016/j.jinorgbio.2021.111436
https://doi.org/10.1016/j.jinorgbio.2021.111436
Publikováno v:
ChemMedChem. 11:2188-2193
Iron depletion using iron chelating agents has been recognized as a promising anti-tumor therapeutic strategy. We herein report a novel theranostic agent for targeted iron chelation cancer therapy and near IR optical imaging. The theranostic agent wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e874d8351429f5a1bf78be3acffbddf0
https://doi.org/10.1002/cmdc.201600072
https://doi.org/10.1002/cmdc.201600072
Publikováno v:
Cancer Letters. 374:31-43
Nanocarriers (NCs) are a group of nano-sized vehicles devised to deliver drugs to targeted malignant tissues or organs that provide remarkably improved targeting efficiency and therapeutic efficacy for cancer therapy. A variety of NCs have been devel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c44d59285bd0449f52a2d9722f7e8c1f
https://doi.org/10.1016/j.canlet.2016.01.050
https://doi.org/10.1016/j.canlet.2016.01.050